0512 (0512) Fair Value & Analysis

Healthcare · Market cap HK$16.5B

0 0512 0512 · HK

PriceHK$4.70

Fair ValueHK$6.02

Upside+28.1%

Quality45/100

Evidence: High Range HK$4.23 – HK$7.53

Fair value as of: Jul 1, 2026

From 26 valuation models · updated today

Share price −7.2% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$4.57 – HK$9.50 · fair‑value band HK$4.23 – HK$7.53 · the HK$4.70 price screens below the HK$6.02 fair value. As of Jul 1, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0512 (0512) currently trades at HK$4.70, while our model-based Fair Value estimate is HK$6.02 — implying the stock looks roughly 28.1% undervalued today. We read business quality at 45/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 0512 generated revenue of HK$12.3B at a net margin of 10.1%. Revenue grew 10.3% year over year. It earns a return on equity of 7.4%. Net debt stands at HK$3.6B. Fundamentals as of Jul 1, 2026

Key figures & financial health

Revenue (TTM) HK$12.3B

Revenue growth (YoY) +10.3%

Net margin 10.1%

Return on equity 7.4%

Free cash flow HK$774M FY2025

P/E ratio 13.4

More key figures

Operating margin 9.3%

EPS (TTM) HK$0.3300

Dividend yield 3.5%

EPS growth (YoY) -92.1%

Net debt HK$3.6B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 1, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

0512 reported revenue of HK$12.3B in FY2025 versus HK$8.6B in FY2021, a compound +9.3%/yr. Reported net income was HK$1.2B in FY2025, compounding −15.2%/yr from FY2021.

Revenue +9.3%/yr

FY21 HK$8.6B

FY22 HK$9.6B

FY23 HK$10.5B

FY24 HK$11.6B

FY25 HK$12.3B

Net income −15.2%/yr

FY21 HK$2.4B

FY22 HK$2.1B

FY23 HK$1.9B

FY24 HK$2.5B

FY25 HK$1.2B

Is 0512 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 1, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥47.01	¥26.59	-43%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,782	₹915.92	-49%
Zoetis Inc Z1TS34	R$26.19	R$26.01	-1%
Hansoh Pharmaceutical Group 3692	HK$29.58	HK$18.75	-37%
Divi's Laboratories Limited DIVISLAB	₹6,788	₹2,035	-70%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 0512 (0512) undervalued?

As of Jul 1, 2026, our model estimates a fair value of HK$6.02 versus a price of HK$4.70 — about +28% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 0512?

Our model-based fair value for 0512 is HK$6.02 (as of Jul 1, 2026), built from audited fundamentals. The current price is HK$4.70.

What is the quality score of 0512?

0512 has a Quality Score of 45/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 0512 (0512)?

0512 reported trailing-twelve-month revenue of about HK$12.3B (latest available figure, as of Jul 1, 2026).

What is the net profit margin of 0512?

The net profit margin of 0512 is about 10.1%, meaning it keeps roughly 10.1% of revenue as net income. Based on the latest reported figures.

Does 0512 pay a dividend?

0512 currently shows a dividend yield of about 3.54% relative to its recent price (as of Jul 1, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.